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INTRODUCTION 
 
 
 The world today is witnessing an epidemic of diabetes 
mellitus.1Globally and nationally, diabetes and its complications has become the 
most important contemporary and challenging health problem.  
 It is estimated that there will be more than 200million diabetics 
in the world within the next 10 years. India has already become the diabetes 
capital of the world with over 30 million affected patients that is alarmingly just 
a tip of the iceberg and is expected to touch the 55million mark in 2025.1 
 The impact of diabetes on both the health of the individual and 
the health care system resides almost entirely in the long term complications of 
diabetes. 
 The FRAMINGHAM HEART STUDY revealed marked 
increase in peripheral arterial disease, congestive heart failure, coronary artery 
disease, myocardial infarction and sudden death(The risk increases from 1 to 5 
fold) in diabetics.2 
 The American Heart Association recently designated DM as a 
major risk factor for cardiovascular disease along with other major risk 
factors(smoking,hypertension and hyperlipidemia)3 
 Though DM is associated with a multitude of cardiovascular 
complications recent studies have suggested structural myocardial involvement 
termed “DM Cardiomyopathy”4. Myocardial involvement in diabetes may occur 
relatively early in the course of the disease,15 initially impairing the diastolic 
relaxation and when more extensive resulting in decreased myocardial 
contraction. Prior to the development of symptomatic CHF sub-clinical LV 
dysfunction (systolic and diastolic) does  exist for some time.5 
 Further, increased LV mass has been documented in Type 2 
Diabetes even in normotensive individuals at an early stage. LVH is an ominous 
prognostic sign and independent risk factor for further cardiac events13 and 
hence identification of this subset of patients would enable early interventional 
strategies that could decrease the incidence of cardiac events. 
 There have been few studies that have evaluated the 
development of systolic and diastolic LV dysfunction and LV mass in Type 2 
DM patients, who are normotensive and have no cardiac symptoms.11  
 The present study was undertaken to make further inroads into 
this aspect of diabetes that would have far flung implications in management of 
diabetes as a whole. 
  
 
 
AIM OF THE STUDY 
 
 
 
 
 Echocardiographic assessment of left ventricular functional and structural 
abnormalities in Type 2 DM patients who are normotensive and without 
any cardiac symptoms. 
 To assess the relationship between the duration of diabetes mellitus and 
the development of LV structural and functional abnormalities 
 
 
 
 
 
 
 
 
 
 
 
 
 
 REVIEW OF LITERATURE 
 
 
Definition: 
 DIABETES MELLITUS is defined as a syndrome characterized by 
chronic hyperglycemia, associated with disturbances of carbohydrate, fat and 
protein metabolism due to absolute or relative deficiency in insulin secretion 
and/or action.  
 In view of the wide heterogeneity, Diabetes is regarded as a “syndrome” 
rather than a disease entity.1 
 
Classification: 
 This classification is based on the pathogenic process that leads to 
hyperglycemia as opposed to earlier criteria that included the age of onset and 
type of therapy.3 
  
The classification of DM: 
1. Type 1 DM    (β cell destruction, usually leading to absolute insulin 
deficiency) 
A: Autoimmune mediated 
B: Idiopathic 
2. Type 2 DM    (may range from predominantly      insulin resistance with 
relative insulin deficiency to a predominantly insulin secretory defect 
with insulin resistance) 
3. Other types: 
 Genetic defects of β cell function characterized by mutation in: 
1. Hepatocyte nuclear transcription (HNF) 4α MODY 1 
2. Glucokinase      MODY2 
3. HNF-1α      MODY3 
4. Insulin promoter Factor (IPF) 1               MODY4 
5. HNF-1β                            MODY5 
 Genetic defects in insulin action 
1. Type A insulin resistance 
2. Leprechaunism 
3. Lipoatrophic diabetes 
 Disease of the exocrine pancreas 
 Endocrinopathies 
 Drugs, Toxin induced 
 Infections 
 Other genetic syndromes 
   4. Gestational Diabetes Mellitus (GDM) 
 
 
TYPE 1 DIABETES MELLITUS: 
This was previously known as Insulin Dependent Diabetes Mellitus 
(IDDM). These patients require insulin for survival, as the endogenous insulin 
secretion is almost absent in them. This disease has its onset most often in 
childhood and adolescence, although it may occur at any age. Though usually 
abrupt in onset, it can be protracted in its course. Genetic factors, autoimmunity 
and environmental factors play a major role in the causation and the 
precipitation of Type1 diabetes. 
 The auto immune aetiology of the disorder is well recognized by the 
presence of immune markers, like Islet cell antibodies (ICA), Insulin 
autoantibodies and antibodies against 64KD antigen. 
 Type 1 DM comprises of two broad categories, Type 1A and Type 1B. 
Type 1A diabetes results from autoimmune beta cell destruction, which usually 
leads to insulin deficiency. Type1B diabetes is characterized by insulin 
deficiency of unknown aetiology, with lack of immunological markers 
indicative of autoimmune destructive process of β cell. 
 
Pathogenesis: 
  Type 1 DM develops as a result of synergetic effect of genetic, 
environmental and immunological factors that ultimately destroy the β cells. 
Individuals with a genetic susceptibility have normal cell β cell mass at birth, 
but begin to lose β cells secondary to autoimmune destruction that occurs over 
months to years. The autoimmune process is thought to be triggered by an 
infectious or environmental stimulus and to be sustained by a beta cell specific 
molecule. In the majority of the individuals immunological markers appear 
after the triggering event, but before diabetes become clinically overt. β cell 
mass then begins to decline and insulin secretion becomes progressively 
impaired, although normal glucose tolerance is maintained. Features of diabetes 
do not become evident until a majority (>80%) of β cells are destroyed. At this 
point, the residual functional β cells still exist, but are insufficient in number to 
maintain glucose tolerance. The events that contribute to the transition from 
glucose intolerance to frank diabetes are associated with increased insulin 
requirements, as might occur during infections or puberty. 
 
Various factors can be attributed to the pathogenesis of Type 1 DM:  
1. Genetic factors 
  Genetic contribution to Type 1DM involves multiple genes. The 
concordance of Type 1DM in identical twins is between 30-70%3, indicating 
that additional modifying factors must be involved in determining whether 
diabetes develops or not. The major susceptibility gene for Type1DM is located 
in HLA region on chromosome 6. Most individuals with Type 1 DM have HLA 
DR3/DR4 halotype. Refinements in genotyping of HLA loci have shown that 
the halotypes DQA1*0301, DQB1*0302, DQA1*501 and DQB1*0201 have 
the strongest association with Type 1 DM.  
2. Autoimmune factors: 
  Pathologically, the pancreatic islets are infiltrated with 
lymphocytes (in a process termed insulitis) due to autoimmunity, leading to 
destruction of the β cells. As a result, the following abnormalities appear in the 
immune system; 
a. Islet cell autoantibodies 
b. Activated lymphocytes in the islets, peripancreatic lymphnodes and 
the systemic circulation. 
c. T lymphocytes that proliferate when stimulated with islet proteins, 
and  
d. Release of cytokines within the insulitis. 
3. Immunological markers: 
 Islet cell autoantibodies are present in the majority (75%) of individuals 
diagnosed as Type 1DM.This includes antibodies to GAD (Glutamic acid 
decarboxylase) 65, IA-2/ICA-512 and Islet gangliosides. 
4. Environmental factors: 
 Various environmental factors have been proposed to trigger the 
autoimmunity in genetically susceptible individuals. They are mainly viral 
infections (Coxsackie and Rubella), early exposure to bovine milk proteins and 
nitrosourea compounds. 
 
 
TYPE 2 DIABETES MELLITUS 
 Type 2 DM is a heterogenous disorder with a complex aetiology that 
develops in response to genetic and environmental influences. Central to the 
development of Type 2 DM are Insulin resistance and Abnormal insulin 
secretion. Although controversy remains regarding the primary defect, most 
studies support the view that insulin resistance precedes insulin secretory 
defects. 
Genetic considerations: 
   Although the major genes that predispose to this disorder 
have yet to be identified it is clear that the disease is polygenic and 
multifactorial. The concordance of Type 2 DM in identical twins is between 70-
90%3. If both parents have Type2DM the offspring have risk approaching 40%. 
Pathogenesis:  
  Type 2 DM is characterized by 3 pathophysiological abnormalities: 
      1. Peripheral insulin resistance 
      2. Impaired insulin secretion 
and 3. Excessive hepatic glucose production 
Peripheral insulin resistance:  
In early stages glucose tolerance remains normal despite insulin 
resistance as the pancreatic β cells compensate by increased insulin output. 
However as the insulin resistance and compensatory hyperinsulinemia progress, 
the pancreatic islets in certain individuals are unable to maintain the 
hyperinsulinemic state. Thus begins a spectrum from impaired glucose tolerance 
to overt diabetes mellitus reflecting the progress towards β cell failure. 
 Insulin resistance results from a combination of genetic susceptibility and 
obesity. Insulin resistance impairs glucose utilization by insulin sensitive tissues 
and increases hepatic glucose output, both effects contribute to hyperglycemia. 
Increased hepatic glucose output and decreased peripheral glucose utilization 
account for the increased fasting plasma glucose levels and postprandial 
hyperglycemia respectively. The molecular mechanism of postreceptor defects 
include (a). Polymorphism in IRS-1    (b)PI-3 kinase signaling defects, which 
reduces translocation of GLUT4 to the plasma membrane and (c) elevated levels 
of free fatty acids in obese individuals results in impaired glucose utilization in 
skeletal muscle, promote glucose production by the liver and impair beta cell 
function. 
Impaired insulin secretion: 
   The cause of impaired insulin secretion in type 2 DM is 
unclear. It is hypothesized that this may be due to (a) Islet amyloid 
polypeptide/amylin. (Amylin has been reported to lower basal and insulin 
stimulated glycogen synthetase in the muscle and also to inhibit glucose 
stimulated insulin secretion) (b)Glucotoxicity. Chronic hyperglycemia 
paradoxically impairs beta cell function. (c) Lipotoxicity. Elevated free fatty 
acids and dietary fat worsen islet function. 
 
Increased hepatic glucose production 
  In type2 DM, insulin resistance in the liver reflects the failure of 
hyperinsulinemia to suppress neoglucogenesis which results in fasting 
hyperglycemia and decreased glycogen storage by the liver in the postprandial 
state. 
 .  
Risk factors for Type 2 DM: 
1. Family history of Diabetes. 
2. Obesity(BMI≥25kg/m2) 
3. Habitual physical inactivity 
4. Race/Ethnicity 
5. Previously identified IFG or IGT 
6. History of GDM or delivery of baby>4kg 
7. Hypertension(BP≥140/90mmHg) 
8. HDL cholesterol level ≤35mg/dl), or TGL level ≥250mg/dl 
9. Polycystic ovary syndrome or Acanthosis nigricans 
10. History of Vascular disease 
 
 
Differentiation of Type 1 and Type 2 DM by clinical criteria: 3 
S.No Type 1 DM Type 2 DM 
1 Onset of disease prior to age of 
30yrs 
Onset of disease after 30years 
2 Lean body habitus 80%obese(elderly individually may be 
lean) 
3. 
 
Requirement of insulin as  the 
initial therapy  
May not require insulin therapy initially 
4. Propensity to develop 
ketoacidosis 
Not usually prone for ketoacidosis 
5. Associated with other 
autoimmune 
disorders(eg.autoimmune 
thyroiditis,pernicious anaemia 
and vitiligo) 
Associated with conditions like 
hypertension, dyslipidemia, PCOD and 
cardiovascular disease. 
6. Presence of ICA and GAD 
Antibodies 
 No autoantibodies  
 
 
DIAGNOSIS:3
 Symptoms of Diabetes plus random* blood glucose concentration 
>11.1mmol/L(200mg/dl) 
or 
 Fasting** plasma glucose >7mmol/L(126mg/dl) 
or 
 2hr plasma glucose>11.1mmol/L(200mg/dl) 
during on oral GTT***. 
  
*Random is defined as without regard to time since the last meal. 
** Fasting is defined as no caloric intake for at least 8hrs. 
*** The test should be performed using a glucose load containing the equivalent 
of 75g anhydrous glucose dissolved in water; not recommended for routine use. 
Long term Complications: 
 Although chronic hyperglycemia is an important aetiologic factor leading 
to the complications of DM, four prominent theories have been proposed to 
explain how hyperglycemia might lead to the chronic complications:  
1. Formation of advanced glycosylation end products (AGEs) via 
nonenzymatic glycosylation of intra and extracellular proteins. 
2. Increased metabolism of glucose through the sorbitol pathway by the 
enzyme Aldose reductase.  Sorbitol in turn increases the cellular 
osmolality, generates reactive oxygen species and alters the redox 
potential and thus leads to cellular dysfunction. 
3. Increase the formation of DAG (Diacyl glycerol) leading to activation 
of Protein kinase C which in turn alters the transcription of genes for 
fibronectin, type-IV collagen, contractile proteins and extracellular 
matrix proteins. 
4. Increased formation of Fructose-6-phosphate through the Hexosamine 
pathway which may alter the function of nitric oxide synthase or by 
changes in  the gene expression of TGF-β and PAI-1(Plasminogen 
activator inhitbitor1) 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
S.No.     Chronic complications of DM 
 
1. Macroangiopathy Coronary artery disease, Cerebrovascular disorder, 
Peripheral vascular disease 
2. Microangiopathy Retinopathy, Macular edema, Nephropathy, 
Neuropathy(Sensory, Motor), Autonomic 
3.  Others  Dermatopathy, GIT (gastroparesis, 
diarrhea),Genitourinary(Uropathy, sexual 
dysfunction), Infectious, Cataract, Glaucoma 
LV STRUTURAL AND FUNCTIONAL ABNORMALITIES 
NORMAL LV FUNCTION 
The three basic events of the cardiac cycle are 
1. LV contraction 
2. LV relaxation  
3. LV filling. 
1. LV Contraction  
It comprises of 1.Isovolumic contraction phase extending from closure of 
mitral and tricuspid valve to the time when pressures in the left and right 
ventricles exceed the pressures in the aorta and the pulmonary artery 2.Phase of 
ventricular ejection that begins as the aortic and pulmonary valves open and 
ends when the ventricular pressures drop rapidly. 
 
2. LV Relaxation  
It comprises of i). Protodiastole (Phase of reduced ejection) the period 
when the ventricular pressures drop very rapidly and ends when  the 
momentum of ejected blood is overcome and aortic and pulmonary valve close. 
ii). Isovolumic ventricular relaxation: Begins with closure of the aortic and 
pulmonary valve and ends with the opening of AV valves as ventricular 
pressure falls below the atrial pressure. 
3. Left ventricular filling:  
It comprises 1.Rapid filling phase which starts as pressure in the ventricle 
drops below the left atrial pressure and the mitral valves open. This period of 
rapid filling ends when pressure in the atrium and ventricle equalize. 2. 
Diastasis: virtually no flow into the ventricle is seen during this phase 3.Atrial 
systole (Late diastolic phase). 
 
LV SYSTOLIC FUNCTION: 6 
  The determinants of LV systolic function are 1.preload 2.afterload 
3.myocardial contractility and 4.heart rate 
The specific indices used to evaluate LV systolic function are: 
1. Ejection fraction 
 Ejection fraction is defined as the ratio of the stroke volume to end 
diastolic volume. 
  EF = EDV – ESV/EDV  × 100(%) 
 The normal value of LVEF is 55-75%. 
2. End systolic ventricular volume/dimension: 
 ESV is strongly afterload dependent and is relatively independent of 
preload. It is useful to assess LV function in patients with valvar regurgitation. 
3. Other indices:  
Include VCF (Velocity of circumferential fibre) shortening, Afterload 
corrected VCF, Slope of End systolic pressure volume relationship, End systolic 
stiffness, Preload recruitable stroke work and the Maximum rate of pressure 
rise. 
LV DIASTOLIC FUNCTION6 
  Assessment of cardiac performance has traditionally focused on 
systolic function. More recently however diastolic function has been found to 
play an important role in cardiac morbidity and mortality. Diastolic function is 
influenced importantly by ventricular structure and composition. However, 
clinically, four phases of diastolic function need to be distinguished 
1.isovolumetric relaxation 2.early rapid diastolic filling (E) 3.slow ventricular 
filling (Diastasis) and 4. late atrial filling (A).  
 Diastolic function is influenced by several factors which include 
1.myocardial relaxation 2.ventricular filling 3.elastic recoil 4.heart rate and 
5.atrioventricular pressure gradient.  
 
 
  
Specific indices used to evaluate diastolic dysfunction include: 
 
1. IVRT (Intraventricular isovolumetric relaxation time):  
This is the interval from the aortic valve closure to mitral valve opening. 
Normal: 70-90millisecond 
2. Peak mitral flow velocity  
Peak mitral flow velocity of early rapid filling wave (E) and Peak 
velocity of late filling wave (A) due to atrial contraction are expressed as E/A 
ratio. Normal >1. 
3. Deceleration time (DT):  
This is the interval from the peak of the E velocity to extrapolation to 
baseline. Normal <240ms. 
4. Other indices include:  
Pulmonary vein flow velocities, tricuspid flow velocities and hepatic vein 
flow velocities and SVC flow velocities. 
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The rate of myocardial relaxation and compliance change with aging, so 
that, different diastolic filling patterns are expected for different age groups.  
 
 Abnormalities of LV systolic function:  
 This is usually identified on echocardiograhic measurement of Ejection 
Fraction. EF <55% denotes LV dysfunction.  
Abnormalities of LV diastolic function: 6 
1. Diastolic abnormalities:  
Characterized by abnormal filling indices, they are commonly identified 
on echo by prolonged IVRT, however, these patients have no clinical 
symptoms. In this situation the ventricle is able to compensate for abnormal 
diastolic function and to maintain a normal level of left ventricular filling 
pressure. 
E 
AT DT 
Mitral valve Inflow Mitral valve Inflow 
 2.  Diastolic dysfunction:  
Characterized by increased diastolic filling pressure which may be 
responsible for the occurrence of dysnoea especially during exercise. 
 3. Diastolic heart failure:  
Associated with clinical signs like PND and orthopnoea. 
  
Echocardiographic classification of diastolic filling27 
 DT 
(msec) 
IVRT 
(msec) 
MITRAL  
E/A 
PVS2&PVd 
Normal 160-240 70-90 1-2 PVS2≥PVd 
Impaired 
Relaxation 
>240 >90 <1 PVS2>>PVd 
Pseudo 
normal 
160-200 <90 1-1.5 PVS2<PVd 
Restrictive 
filling 
 
<160 <90 >1.5 PVS2<<PVd 
 
The clinical differentiation of the two forms of heart failure is of utmost 
importance as treatment modalities entirely differ. 
LEFT  VENTRICULAR  MASS 
 The role of LV mass estimation and diagnosis of LVH in cardiovascular 
disease management is based on epidemiological research and clinical grounds.  
In general, heart size increases during infancy and adolescence due to body size 
enlargement, and at this stage, the gender difference becomes prominent. The 
physiological factors8 that contribute to LV mass are: 
1. Gender-women have increased parietal hypertrophy response to 
pressure than men. 
2. Ethnicity-some ethnic groups have higher LV mass(African 
Americans) 
3. Obesity 
4. Age: LV mass progressively increases with age, particularly parietal 
thickness. However, Dannenberg and coworkers demonstrated that LV mass 
did not increase with age in a healthy sub-sample of the Framingham study, 
suggesting that most of the supposed physiological increase is caused by other 
determinants that include Hypertension, DM with metabolic syndrome, Alcohol 
consumption, Increased salt intake, Smoking and Increased leisure time physical 
activity in men, Blood lipid, Pulmonary function and Heart rate.  
 
Echocardiographic measurement of LV mass is generally calculated 
as the difference between the epicardium delimited volume and the LV chamber 
volume multiplied by an estimate of myocardial density. Both M mode and 2D 
imaging can be employed to calculate LV mass. Despite more than 30 years of 
use Echocardiograph based LV mass calculation and definition are still variable 
among Ultrasound technicians around the world. The Echocardiographic 
criteria to calculate LV mass in this study was: 18 
 
 (RWT) (LVMI)g/m2 
Normal <0.45 <131(men), <100(women) 
Concentric  
Remodeling 
 
>=0.45 
<131(males), <100(females) 
Concentric 
Hypertrophy 
>=0.45 >131(males), >100(Females) 
Eccentric 
Hypertrophy 
<0.45 >131(males), >100(females) 
 
 
DIABETES AND CARDIOVASCULAR DISEASE 
 Diabetes mellitus is an independent risk factor for cardiovascular disease 
(CVD). In the FRAMINGHAM STUDY the risk of CVD for diabetic 
subjects at baseline was two fold higher in men and three to four fold for 
women after adjustment for other risk factors such as dyslipidemia and 
hypertension. More recently NHANES1 study also showed that the diabetic 
population was twice as likely to develop CAD as the nondiabetic population 
with excess mortality . 
The MRFIT STUDY shows that men with diabetes had an absolute risk 
of death due to CAD more than three times than the nondiabetic cohort. 
In the six nation OASIS study6, diabetic patients presenting with 
unstable angina or Non Q MI had increased rate of stroke, CHF and death 
during index hospitalization compared with the non-diabetic group. 
In the Finnish contribution to WHO MONICA (World Health 
Organization Multinational Monitoring of Trends and Determinants of 
Cardiovascular Disease) project, the 1 year mortality was 38% higher for 
diabetic men and 86% higher for women. 
In view of the above, studies have been undertaken in recent times to 
identify structural and functional abnormalities in normotensive diabetics who 
have no cardiac symptoms. Most of the recent studies identified changes in LV 
mass and LV systolic and diastolic function indices even before the patients are 
symptomatic. 
 The main factors that contribute to the increased incidence of 
cardiovascular disease in DM are: 1 
1. The acceleration of atherosclerotic process leading to 
macrovascular disease. 
2. Development of specific cardiomyopathy 
3.  Progressive microvascular disease 
4. Development of autonomic neuropathy 
 
Noninvasive methods have confirmed that fibrosis is a key feature of the 
heart of diabetic patients without evident cardiac disease. Increased level of 
collagen in diabetics have been associated with changes in left ventricular 
diastolic function.11 Chronic hyperglycemia leads to the formation of AGE’s 
that modify the extracellular matrix, resulting in inelasticity of the vessel wall 
and could interfere with myocardial function as well.6 These coupled with 
abnormal myocardial calcium handling result in poor elastic recoil, leading to 
impairment in early rapid diastolic filling(E) manifest by prolonged IVRT and 
DT, and increased Mitral (A) velocity. 
   In the setting of insulin resistance, there is release of free fatty acids from 
adipose tissue into the plasma. FFA becomes the dominant fuel for myocardial 
energy in the form of free fatty acid oxidation within cardiac myocytes. In 
addition, the rise in plasma free fatty acids leads to a decrease in glycolysis and 
glucose oxidation in these cells. Free fatty acid oxidation is a less efficient 
means of generating adenosine triphosphate than glucose oxidation thus 
contributing to chronic left ventricular dysfunction. 
  The impact of glucose intolerance and insulin resistance on cardiac 
structure and function is as follows: 
   
 
   
     
 
 
   
 
 
MATERIALS AND METHODS 
 
 All patients included in the study were taken from the Diabetology 
department of Govt. Rajaji Hospital, Madurai. 
 This is a case control cross sectional study. The study period was from 
August –2005 July 2006. The diagnosis of the cases was based on clinical 
features and WHO criteria for DM. The total number of patients in the study 
group were 60, this  includes 28 males and 32 females. The study group was 
further subdivided into three groups based on the duration of Diabetes. 
 GROUP I: 0-5YEARS 
 GROUP II: 6-10YEARS 
 GROUP III: >10YEARS 
The control group was taken from the Outpatient Dept of Medicine and 
Inpatients admitted for other ailments. This group was designated as GROUP 
IV. Total number of controls was 40, which included 20 males and 20 females. 
All cases and controls were within the age of 40-60 years. Both cases and 
controls were examined and recruited in the study in the same time period. All 
subjects gave informed consent for their participation in the study. 
Inclusion criteria: 
1. All cases of Type 2DM diagnosed by WHO criteria  
2. Age: 40-60 years 
3. BP: <130/85 (at least 3 recordings with the highest recording 
taken into consideration) 
Exclusion criteria were  
1. Systemic Hypertension(BP>140/90) 
2.  Ishaemic heart disease(abnormal E.C.G. and  RWMA on 
Echo) 
3. CHF 
4.  Congenital or Acquired Valvular Heart Disease 
5. CRF 
6. Age>60yrs 
7. cardiac signs and symptoms(exertional dysnoea, chest pain, 
palpitation, raised JVP) 
8. PDR/NPDR   and  
9. Microalbuminuria. 
 
 
Echocardiography: 
Patients were evaluated by 2D and Doppler Echocardiography. All 
examinations were performed using a ALOKA SSD 2000 machine 2.5Mhz 
transducer. The following were registered on assessment: 
 
 
 
 
1.Ejection Fraction2.LV mass 3.Mitral Early filling velocity (E), Mitral 
late atrial filling velocity (A),E/A was then derived 4.IVRT   
and   5.DT. 
Operators blinded to the diabetes diagnosis of the patients performed all 
Echocardiographic measurements. 
Computer Analysis of data was done using the software epidemiological 
information package – 2002 developed by Centre for Disease Control and 
Prevention, Atlanta in collaboration with WHO. 
 Chi – square test was used for tests of significance. 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
A. Comparison of Parameters in Diabetic Group (cases) and non diabetic group 
(Cantnoes)   
Table 1: AGE 
 
Diabetic Non-Diabetic 
Age Group 
No % No % 
40 – 44 14 23.3 10 25 
45 – 49 14 23.3 9 22.5 
50 – 54 9 15 9 22.5 
55 – 59 14 23.3 8 20 
60 & above 9 15 4 10 
Total 60 100 40 100 
Mean 50.25 50.45 
S.D. 6.95 6.06 
p 0.9494 (Not Significant) 
 
 
 
 
 
 
 
 
 
 
 
  
 
Table 2: SEX 
 
Diabetic Non-Diabetic 
Sex 
No % No % 
Male 28 46.7 20 50 
Female 32 53.3 20 50 
p 0.9024 (Not Significant) 
 
 
 
 
 
 
Table 3: EF % 
 
Diabetic Non-Diabetic 
EF% 
No % No % 
Normal 46 76.7 36 90 
Abnormal 14 23.3 4 10 
Mean 60.56 63.82 
S.D. 7.53 7.18 
p 0.1514 (Not Significant) 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Table 4: LV Mass (gm/m2) 
 
Diabetic Non-Diabetic 
LV Mass (gm/m2) 
No % No % 
Normal 39 65 34 85 
Abnormal 21 35 6 15 
Mean 98.77 97.59 
S.D. 24.65 8.45 
p 0.045 (Significant) 
 
 
 
 
 
  
 
 
Table 5: Deceleration Time  
 
Diabetic Non-Diabetic 
Deceleration Time 
No % No % 
Normal 34 56.7 28 70 
Abnormal 26 43.3 12 30 
Mean 205.65 207.6 
S.D. 43.74 32.1 
p 0.2561 (Not Significant) 
 
 
 
 
 
Table 6: IVRT  
 
Diabetic Non-Diabetic 
IVRT 
No % No % 
Normal 21 35 22 55 
Abnormal 39 65 18 45 
Mean 101.65 93.2 
S.D. 25.8 17.5 
p 0.0762 (Not Significant) 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Table 7: E/A Ratio  
 
Diabetic Non-Diabetic 
E/A Ratio 
No % No % 
Normal 25 41.7 28 70 
Abnormal 35 58.3 12 30 
Mean 0.94 1.15 
S.D. 0.28 0.23 
p 0.0099 (Significant) 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Table 8: Pulse Rate per Minute  
 
Diabetic Non-Diabetic 
Pulse Rate 
No % No % 
Normal 46 76.7 40 100 
Abnormal 14 23.3 - - 
Mean 90.55 81.7 
S.D. 12.65 5.52 
p 0.0027 (Significant) 
 
 
 
 
B. Comparison of Parameters within Diabetic Group according to duration of 
diabetics – I) 1 to 5 years II) 6-10 years III) More than 10 years 
   
 
Table 9: AGE 
 
I II III 
Age Group 
No % No % No % 
40 – 44 5 25 6 30 3 15 
45 – 49 4 20 5 25 5 25 
50 – 54 2 10 3 15 4 20 
55 – 59 7 35 3 15 4 20 
60 & above 2 10 3 15 4 20 
Total 20 100 20 100 20 100 
Mean 50.5 48.7 51.9 
S.D. 7.4 7.1 6.3 
p 0.5218 
 
 
 
Table 10: Sex and Duration if Diabetes  
 
I II III 
Sex 
No % No % No % 
Male 9 45 9 45 10 50 
Female 11 55 11 55 10 50 
 
‘p’ Value Between 
I & II  - 0.7506 (Not Significant) 
I & III - 1.000 (Not Significant) 
II & III - 1.000 (Not Significant) 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Table 11: EF% and duration of Diabetes   
 
I II III 
EF% 
No % No % No % 
Normal 18 90 15 75 13 65 
Abnormal 2 10 5 25 7 35 
Mean 60.42 62.7 58.6 
S.D. 6.1 9.6 6.2 
 
‘p’ Value Between 
I & II  - 0.2763 (Not Significant) 
I & III - 0.0636 (Not Significant) 
II & III - 0.73 (Not Significant) 
 
 
  
 
 
 
 
 
 
 
 
 
Table 12: LV Mass (gm/m2) and duration of Diabetes   
 
I II III 
LV Mass 
No % No % No % 
Normal 17 85 13 65 9 45 
Abnormal 3 15 7 35 11 55 
Mean 86.5 98.8 111.0 
S.D. 19.7 30.2 16.5 
 
‘p’ Value Between 
I & II  - 0.2733 (Not Significant) 
I & III - 0.0203 (Significant) 
II & III - 0.3403 (Not Significant) 
 
 
 Table 13: Deceleration Time and duration of Diabetes   
 
I II III Deceleration 
Time No % No % No % 
Normal 12 60 11 55 11 55 
Abnormal 8 40 9 45 9 45 
Mean 192.8 212.0 212.2 
S.D. 48.7 49.5 39.7 
 
‘p’ Value Between 
I & II  - 1.00 (Not Significant) 
I & III - 1.00 (Not Significant) 
II & III - 0.7506 (Not Significant) 
 
 
 
Table 14: IVRT and duration of Diabetes   
 
I II III 
EF% 
No % No % No % 
Normal 6 30 7 35 8 40 
Abnormal 14 70 13 65 12 60 
Mean 108.1 99.5 97.4 
S.D. 20.4 31.3 24.6 
 
‘p’ Value Between 
I & II  - 1.00 (Not Significant) 
I & III - 0.74 (Not Significant) 
II & III - 1.00 (Not Significant) 
 
 Table 15: E/A Ratio and duration of Diabetes   
 
I II III 
E/A Ratio 
No % No % No % 
Normal 10 50 8 40 7 35 
Abnormal 10 50 12 60 13 65 
Mean 1.0 0.94 0.88 
S.D. 0.3 0.29 0.27 
 
‘p’ Value Between 
I & II  - 0.7506 (Not Significant) 
I & III - 0.5223 (Not Significant) 
II & III - 1.00 (Not Significant) 
 
 
 
 
Table 16: Pulse Rate per minute and duration of Diabetes   
 
I II III 
Pulse Rate 
No % No % No % 
Normal 16 80 16 80 14 70 
Abnormal 4 20 4 20 6 30 
Mean 88.2 89.4 94.1 
S.D. 12.1 13.2 12.4 
 
‘p’ Value Between 
I & II  - 0.6526 (Not Significant) 
I & III - 0.715 (Not Significant) 
II & III - 0.715 (Not Significant) 
  
 
 
 
 
 
C. Comparison of parameters within the study group(diabetics) according 
to Sex 
Table 17: Relationship between sex and LV mass 
 
Male Female 
LV Mass 
No % No % 
Normal 24 85.7 15 46.9 
Abnormal 4 14.3 17 53.1 
Mean 97.88 99.54 
S.D. 26 23.79 
p 0.004 (Significant) 
 
    
 
 
 
  
Table 18: Relationship between sex and E/A ratio 
Male Female 
E/A 
No % No % 
Normal 13 46.4 12 37.5 
Abnormal 15 53.6 20 62.5 
Mean 0.948 0.9365 
S.D. 0.303 0.272 
p 0.6618 (Not Significant) 
 
  
Table19: Relationship between sex and pulse rate 
 
 
Male Female 
Pulse Rate 
No % No % 
Normal 25 89.3 21 65.6 
Abnormal 3 10.7 11 34.4 
Mean 85.5 95.0 
S.D. 11.76 11.88 
p 0.0635 (Not Significant) 
 STATISTICAL ANALYSES 
 This study was a cross sectional case control study conducted in 60 cases 
of Type2 DM who satisfied inclusion criteria and 40 age and sex matched 
controls.  The mean age of cases was 50.25 years and controls 50.45years.  
Of the 60 cases 28(46%) were males and 32(53.3%) were females. Of the 40 
controls, 20 were males and 20 were females. 
 The cases were divided into three groups based on the duration of 
diabetes. Group I comprising those with diabetes of 0-5 yr duration while 
Groups II and III comprising those with duration of 5-10yrs and >10yrs 
respectively. The number of cases in each group was 20.  
 The mean age of Group I patients was 50.5yrs. Of the 20 patients in the 
Group,9 were males and 11 were females. 
  The mean age of Group II patients was 48.7yrs. Of the 20 patients in the 
Group, 9 were males and 11 were females. 
 The mean age of Group III patients was 51.7yrs. Of the 20 patients in the 
group, 10 were males and 10 were females. 
 In this study, regarding EF <55% considered to be systolic dysfunction. 
E/A ratio <1, IVRT >90msec and DT >240msec taken as an abnormal diastolic 
dysfunction. 
 Regarding LV Mass male >131gm/m2 and female >101gm/m2 taken as an 
increase LV Mass.  
 Observations of EF revealed that abnormalities were present in 10% of 
Group I, 25% of Group II and 35% of Group III while only 10% of the control 
group(Group IV) showed abnormalities. 
 Observations of LV mass revealed that abnormalities were present in 
15% of Group I, 35% of Group II and 55% of Group III while only 15% of the 
control group(Group IV) showed abnormalities. 
 Observations of DT revealed that abnormalities were present in 40% of 
Group I, 45% of Group II and 45% of Group III while 30% of the control group 
(Group IV) showed abnormalities. 
 Observations of IVRT revealed that abnormalities were present in 75% of 
Group I, 65% of Group II and 60% of Group III while 45% of the control group 
(Group IV) showed abnormalities. 
 Analysis of E/A ratios revealed that abnormalities were present in 50% of 
Group I, 60% of Group II and 65% of Group III. 30% of GroupIV (controls) 
also revealed abnormalities. 
 It was observed that a resting pulse rate >100 was observed in 20% of 
Group I and II and 30% of Group III cases while the pulse rate was within the 
normal range in all controls. 
 
 
 
 
 
 DISCUSSION 
 
 
 In the study, it was observed that 35% of diabetics (cases) and 15% of 
non-diabetics (controls) had increased LV mass, (‘p’ < 0.045) which is 
statistically significant. This is in conformity with other studies as shown below. 
 
Studies by Hirayama et al 13 observed the increased incidence of LV 
mass among diabetics (normotensive and asymptomatic) than non-di abetics. 
Dawson et al11 observed that the prevalence of LVmass abnormalities was 71% 
among diabetics compared to 35% in our study, this may be due to non 
exclusion of hypertensives in the study. Nielsen et al16 observed that increased 
LV mass was found in 51% of diabetics.  
 
Intragroup analyses of cases revealed that Increased LV mass was seen 
in 15% of Group I, 35% of Group II and 55% of Group III. There was 
statistically significant association between Group I and Group III (P < .0203). 
This indicates that the development of increased LV mass is dependent on the 
duration of Diabetes.    
 
 With regard to EF, 23.3% of diabetics and 10% of non diabetics had 
abnormal EF.This was found to be statistically insignificant. (p<0.1514). This is 
in conformance with other studies Hiroyoshima et al, Siwach et al4, Saner et 
al19. However studies by Annonu et al14 observed that diabetics had low EF, 
however the study group included the presence of complications of diabetes 
which were excluded in our study. Further Oirko et al15 also observed low EF 
in diabetics. Thus studies regarding EF abnormalities in DM have observed 
varying results which need to be further investigated. 
 
 Observations of IVRT revealed that 65% of cases and 45% of controls 
show abnormalities. However this was not statistically significant.( (p<0.0762) 
 
 Observations of DT revealed that 43.3% of cases and 30% of controls 
show abnormalities which was found to be statistically significant.(p <0.2561) 
 
 Observations of E/A ratio revealed that 58.3% of cases (diabetics) and 
30% of controls showed abnormalities, which was found to be statistically 
significant. (p<0.0099). 
 The observations on IVRT,DT and E/A ratio are in conformance with the 
study by Siwach et al. wherein 68% of diabetics had E/A <1 compared to 
58.3% in our study Most other studies performed to analyse diastolic function 
abnormalities have taken into account E/A ratio as the single parameter of 
diastolic function. Spiro Qirko et al, and Elizi et al12 observed values of E/A<1 
in 65.8% and 68.9% of diabetes respectively that was statistically significant in 
relation to the controls. This infers that E/A ratio abnormality is an indicator of 
diastolic dysfunction in diabetics. However the reason for the statistically 
insignificant values of DT and  IVRT abnormalities in diabetics are not known. 
Diastolic function abnormalities occur early in the course of disease. This is 
evident by the comparison of E/A ratios in Group I and Group III.  Which 
shows 50% of Group I and 65% of Group III had E/A<1 that was statistically 
insignificant. (p<0.5223).Bonitio et al20 and Spiro Qirko et al also observed 
the same in their studies. 
 
Interestingly, observations of our study revealed increased resting pulse 
rate in diabetics that was subject to statistical analysis. It was observed that 
23.3% of cases (diabetics) and none of controls had increased resting pulse rate 
which was statistically significant.(p<0.0027). This was earlier documented by 
studies by Atheros et al17 and Saner et al. The increase in resting pulse rate is 
probably due to diabetic autonomic neuropathy that was not excluded in our 
study. 
 
Further observations of LV mass between males and females revealed 
that 14.3% of diabetic males and 53.1% of diabetic females had increased LV 
mass which was statistically significant. (p,0.004). This reflects the increased 
(four fold) cardiovascular mortality in diabetic females compared to males (two 
fold) 
 The occurrence  of structural and functional abnormalities in Type 2 DM 
as observed in our study clearly state the importance of Echocardiographic 
assessment(screening) of all Type 2 DM patients even in the absence of cardiac 
symptoms. This is feasible as ECHO is easily available in our setup. 
 
 
 
 
 
 
LIMITATIONS 
 
1. The study was restricted to hospital patients, so its relevance to the 
general population is unknown. 
 
2. Patients with DM usually have silent ischemia and this factor was not 
taken into account in the study. 
 
3. The study is subject to measurement error, subject error and instrument 
error, though carefully designed. 
 
4. Ambulatory BP could not be done this may affect the study group to some 
extent. 
  
5. Smoking, obesity and dyslipidemia were not excluded from the study 
group, this may have some influence on LV mass 9. 
   
The limitations however do not invalidate the main findings of the study. 
 
 
 
 
 
 
 
 
 
SUMMARY 
 
 Echocardiographic assessment of diabetic non-diabetic group 
revealed the following findings: 
 
1. In diabetic, systolic function not significantly affected when compare to 
non-diabetic. 
2. Diabetic have increase LV Mass than non-diabetic. 
3. In diabetes, females have increase LV Mass than male. 
4. The development of LV Mass in diabetic depend upon the duration of 
illness. 
5. IVRT, DT not significantly affected in diabetic when compare to diabetic. 
6. E/A ratio significantly affected between diabetic & non-diabetic. 
7. In diabetes, IVRT, DT & E/A ratio not significantly affected according to 
the duration of illness.     
8. Diabetic have increase resting pulse rate   
 
 
 
 
 
CONCLUSIONS 
 
 
Echocardiographic observation of Type 2 DM patients who are 
normotensive and have no cardiac symptoms revealed: 
 
 Increased LV mass compared to controls, that is well correlated 
with the duration of diabetes and with a female preponderance 
 LV diastolic dysfunction compared to controls, which does not 
correlate with the duration of diabetes mellitus, reflecting the 
occurrence of dysfunction early in the course of disease. 
 LV systolic function analyzed through EF is not significantly 
affected in diabetics. 
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TARGET ORGAN ABNORMALITIES IN TYPE 2 DIABETES MELLITUS 
Name :      Sl. No : 
Age  :       IP.No : 
Sex :       OP.No : 
Duration of Diabetes: 
 
Complaints   General Examination  Investigations  
Giddiness   Pallor  Urine Albumin  
Palpitation   Jaundice  Hb  
Breathlessness   Cyanosis  ESR  
Chest discomfort   Clubbing  Blood Sugar  
Headache   LNE  Urea  
Vertigo   Pedal oedema  Sr. Creatinine  
Weakness   Pulse rate     /min  Sr. Cholesterol  
Dec. in work 
performance 
  Peripheral pulse  ECG  
Swelling of Legs   BP Rt UL -mmHg  HR  
Bleeding Nose         Lt UL -mmHg  PR  
Seizures          Rt LL -mmHg  QRS QT  
Sexual 
Dysfunction 
  CVS  AXIS  
Others   Apical Impulse  ST- T Segment   
   JVP  Q Waves   
Personal History   Precardium Pulsations     
Smoker   Epiugatric Pulsations     
Alcholic   S1    
Thyroid   S2    
Family History   Added sounds    
DM   Murmur    
HT   RS    
CAD   Breath Sounds    
Past History   Added Sounds    
DM   Abdomen    
TIA       
CVA   CNS    
 
ECHO CARDIOGRAPHY 
 
DIASTOLIC FUNCTION INDICES 
 
IVRT Mitral E m/s  A m/s E/A 
 Tricuspid E m/s  A m/s E/A 
 
Deceleration Time (DT) 
 
SYSTOLIC FUNCTION INDICES 
 
IVS d  LVPW d  LVID d  
IVS s  LVPW s  LVID s  
 
 
EF  %  LV Mass 
 
 
Valves  
 
Mitral  Tricuspid 
 
Aortic 
 
 
RETINOPATHY 
 
 
 
 
 
 
MICROALBUMINURIA 
 
 
 
 
 
 
CT SCAN 
 
 
Diagnosis at presentation 
 MASTER CHART 
 
 
Sl.No GROUP SEX AGE DURATION EF% LV MASS DECE.TIME IVRI E/A PE TYPE 
1 I 2 55 1 56 72.28 240 110 0.635 104 A 
2 I 2 40 3 58.3 69.81 140 107 0.721 100 A 
3 I 1 60 3 66 107.33 246 142 0.9 76 A 
4 I 1 60 5 66 61.61 242 139 0.88 92 A 
5 I 1 40 1 55 64.86 178 110 1.54 76 A 
6 I 1 59 3 63 124.4 150 110 1.16 80 A 
7 I 2 50 1 64 71.76 135 82 1.11 80 A 
8 I 2 45 1 50 104.16 241 98 0.823 108 A 
9 I 2 58 4 52 80.98 245 99 0.789 90 A 
10 I 2 55 4 55 112.19 244 133 0.783 90 A 
11 I 2 48 1.5 60 81.92 121 89 1.11 92 A 
12 I 2 46 1 56 96.96 167 110 1.13 80 A 
13 I 1 40 4 57 68.09 160 78 1.68 110 A 
14 I 1 55 4.5 59 59.63 247 139 0.623 78 A 
15 I 1 40 1 62 62.12 146 130 1.261 86 A 
16 I 1 51 3 64 102 138 87 1.11 78 A 
17 I 1 55 4 63 94.21 245 112 0.86 76 A 
18 I 2 58 5 58 110.21 241 117 0.58 110 A 
19 I 2 42 2 76 92.11 160 86 1.12 80 A 
20 I 2 46 3 68 94.2 170 84 1.26 78 A 
 21 II 2 42 8 73 54 149 75 85 90 A 
22 II 1 45 6 72 132.4 242 110 0.8 98 A 
23 II 1 60 7 75 65.5 230 117 0.68 82 A 
24 II 1 42 6 69 135.4 248 100 1 80 A 
25 II 2 50 6 55 89.88 206 92 1.17 78 A 
26 II 1 60 8 59 84 244 153 0.66 112 A 
27 II 1 60 9 62 126.6 242 105 0.605 80 A 
28 II 1 57 6 55 108 180 16 1.22 80 A 
29 II 1 50 6 74 102 120 90 1.14 110 A 
30 II 2 45 7 50 115.4 241 126 0.9 90 A 
31 II 2 45 9 77 64.45 230 125 0.779 82 A 
32 II 2 56 6 66 71.48 246 111 0.793 90 A 
33 II 2 40 6 52 113.52 244 139 0.75 92 A 
34 II 2 40 8 64 116.26 203 71 1.16 110 A 
35 II 2 52 9 54 141.66 245 135 0.5 112 A 
36 II 2 41 7 58 78 132 82 0.9 80 A 
37 II 2 55 7 51 153 244 112 0.8 96 A 
38 II 2 42 8 77 63.85 160 89 1.75 82 A 
39 II 1 45 9 50 60.84 224 61 1.1 68 A 
40 II 1 47 8 60 100 210 80 1.2 75 A 
41 III 1 50 16 50 133.36 121 53 1.16 80 A 
42 III 2 42 11 71 123.42 242 114 0.631 100 A 
43 III 1 60 13 53 70.55 263 107 0.581 80 A 
 44 III 1 58 12 59.5 114.77 244 95 0.557 80 A 
45 III 1 55 14 52 144.57 248 150 0.879 100 A 
46 III 1 60 14 63 90.9 170 110 0.54 100 A 
47 III 2 42 11 52 109.07 241 110 0.616 107 A 
48 III 2 60 14 51 105.45 170 100 1.36 90 A 
49 III 2 52 16 64 111.44 178 43 0.818 120 A 
50 III 2 49 15 59 120.2 180 76 1.3 105 A 
51 III 1 54 13 55 94 247 112 0.84 82 A 
52 III 1 47 11 68 105.7 190 84 1.21 78 A 
53 III 1 60 16 53 104.7 250 120 0.58 94 A 
54 III 1 46 14 58 101.2 260 114 0.681 84 A 
55 III 1 44 13 60 122 194 84 1.1 79 A 
56 III 2 48 15 64 115.7 178 81 1.21 110 A 
57 III 2 56 17 58 120 236 117 0.86 100 A 
58 III 2 57 11 67 94 190 78 1.12 86 A 
59 III 2 45 15 62 126 194 89 0.85 102 A 
60 III 2 53 14 53 112 247 111 0.789 105 A 
61 IV 2 41  72 84.12 140 86 1.16 80 B 
62 IV 2 44  69 98.1 178 76 1.36 78 B 
63 IV 2 59  60 105.76 246 117 0.856 76 B 
64 IV 2 60  58 94.7 242 115 0.78 90 B 
65 IV 2 49  64 102.7 196 74 1.47 77 B 
66 IV 1 40  77 94.8 199 84 1.17 78 B 
 67 IV 1 48  68 86.7 184 76 1.26 80 B 
68 IV 1 60  60 79.06 241 117 0.96 84 B 
69 IV 1 53  71 107 211 94 1.24 82 B 
70 IV 1 44  74 97.06 194 76 1.47 74 B 
71 IV 2 47  62 104.07 210 90 1.26 80 B 
72 IV 2 55  58 96.7 247 119 0.96 81 B 
73 IV 2 54  62 84.56 199 83 1.34 84 B 
74 IV 2 42  69 96.55 187 76 1.47 81 B 
75 IV 2 48  59 104.37 210 84 1.12 83 B 
76 IV 1 51  62 102.04 217 82 1.35 78 B 
77 IV 1 40  74 91.7 196 77 1.4 72 B 
78 IV 1 60  55 111.07 257 130 0.856 90 B 
79 IV 1 55  67 87.07 241 111 0.9 80 B 
80 IV 1 50  55 93.7 194 69 1.2 83 B 
81 IV 2 45  67 92.7 104 76 1.34 87 B 
82 IV 2 51  54 109 242 109 0.857 87 B 
83 IV 2 55  58 87.07 187 89 1.41 69 B 
84 IV 2 44  74 105.06 194 67 1.07 77 B 
85 IV 2 49  71 93.6 196 87 1.34 84 B 
86 IV 1 54  64 107.06 184 81 1.12 78 B 
87 IV 1 49  62 91.07 196 89 1.05 76 B 
88 IV 1 55  52 106.07 241 116 0.76 82 B 
89 IV 1 44  66 98.6 187 84 1.4 78 B 
 90 IV 1 58  51 112.7 257 120 0.78 96 B 
91 IV 2 54  58 96.7 187 83 1.4 79 B 
92 IV 2 43  72 79 189 91 1.26 84 B 
93 IV 2 47  67 99.99 197 78 1.313 80 B 
94 IV 2 56  52 98.6 241 120 0.87 92 B 
95 IV 2 49  70 97.57 196 95 1.4 78 B 
96 IV 1 50  72 106.3 211 93 1.15 82 B 
97 IV 1 58  55 107.6 257 123 0.96 84 B 
98 IV 1 53  58 94.67 216 94 1.3 87 B 
99 IV 1 44  72 101.07 187 84 1.15 90 B 
100 IV 1 60  62 97.54 247 113 0.678 87 B 
 
A – Cases,  B- Controls, 1 – Male, 2-Female, Gr. I - Cases 0-5Years, Gr. II – Cases 6-10 Years, Gr.III – Cases More than 10 
Years. Gr. IV – Controls.    
 
 
 
 
 
 
  
 
Comparison of Abnormal LV Mass in cases and control 
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Comparison of Abnormal E/A Ratio in cases and controls 
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LV Mass (gm/m2) and duration of Diabetes 
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Relationship between Sex and LV Mass in cases 
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Mitral flow velocity and Doppler tissue in patient with diastolic dysfunction and impaired 
relaxation : Brawnwald  7th 2005  
 
  
 
  
  
 
  
 
